New data on a higher-dose version of semaglutide has shown even greater potential in aiding weight loss. The new 7.2 mg dose, tested in a phase 3b study, resulted in more significant weight loss compared to the current 2.4 mg dose, which is already available for obesity treatment.
For more information about FIT Medical Weight Loss programs and how we can help you reach your weight loss goals contact one of our clinics below or click here for more information. Our health coaches are ready to help you lose weight, and enjoy doing it! Reach out today to get started.
Key Findings from the STEP UP Study: In the STEP UP study, which involved 1,407 participants, those taking the 7.2 mg dose of semaglutide lost an average of 20.7% of their body weight after 72 weeks. This was significantly higher than the 17.5% weight loss achieved with the 2.4 mg dose and far greater than the 2.4% weight loss observed in the placebo group.
Higher Dose, Higher Success Rates: An impressive 33.2% of participants who received the 7.2 mg dose achieved weight loss of at least 25%, compared to just 16.7% of those on the 2.4 mg dose and none in the placebo group. These results further solidify semaglutide’s role in helping people achieve substantial weight loss.
Safety and Tolerability: The higher-dose semaglutide appeared to be safe and well tolerated in the study, with gastrointestinal side effects, which are common in the GLP-1 receptor agonist class, being the most frequently reported.
What’s Next for Semaglutide: Detailed results from the STEP UP study are expected to be presented at an upcoming medical meeting. Additionally, a separate study, STEP UP T2D, is exploring the effects of the 7.2 mg dose in patients with Type 2 diabetes and obesity, with results expected soon.
For more information, check out the source article here.